Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Non Operating Income (2018 - 2025)

Corcept Therapeutics (CORT) has disclosed Non Operating Income for 8 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 19.04% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.7 million through Dec 2025, down 11.71% year-over-year, with the annual reading at $21.7 million for FY2025, 11.72% down from the prior year.
  • Non Operating Income hit $5.4 million in Q4 2025 for Corcept Therapeutics, up from $5.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $6.7 million in Q4 2024 to a low of $72000.0 in Q3 2021.
  • Historically, Non Operating Income has averaged $3.4 million across 5 years, with a median of $4.3 million in 2023.
  • Biggest five-year swings in Non Operating Income: crashed 89.11% in 2021 and later skyrocketed 4376.25% in 2023.
  • Year by year, Non Operating Income stood at $72000.0 in 2021, then skyrocketed by 2368.06% to $1.8 million in 2022, then surged by 189.25% to $5.1 million in 2023, then soared by 30.31% to $6.7 million in 2024, then decreased by 19.04% to $5.4 million in 2025.
  • Business Quant data shows Non Operating Income for CORT at $5.4 million in Q4 2025, $5.0 million in Q3 2025, and $5.0 million in Q2 2025.